A novel phenotypic assay for monitoring hepatitis B virus (HBV) drug resistance during antiviral treatment

Durantel, David; Durantel, Sandra; Pichoud, C; Werle, Bettina; Brunelle, Marie-Noëlle; Trépo, Christian; Zoulim, Fabien

doi:10.1016/s0168-8278(03)80434-8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These experimental approaches are limited to a small region of the genome and give no information on the effect of the mutation on other regions of the genome in terms of replication yield phenotype, viral fitness, virulence and drug susceptibility. In contrast, cloning of the whole HBV genome and transfection into cell lines allows comparison of the viral replication capacity either between clones or viruses obtained before, during or after therapy [47,48].…”

Section: Table 3 Antiviral Treatment Effect Summarymentioning

confidence: 99%

Management of Antiviral Resistance in Patients with Chronic Hepatitis B

et al. 2004

View full text Add to dashboard Cite

A meeting of physicians and scientists involved in the management of chronic hepatitis B (CHB) was held to review current scientific data regarding antiviral resistance in hepatitis B virus (HBV) infection. The goals of the meeting were to describe current treatments for CHB, discuss emerging issues in HBV drug resistance and to delineate patient monitoring, including markers for resistance, during administration of antiviral therapy. The aim of this review article is to provide treating physicians with a framework for the management of CHB in the context of antiviral resistance. Definitions of primary and secondary antiviral treatment failure can be used to aid monitoring and early diagnosis of drug resistance before disease progression occurs as a consequence of viral breakthrough. Primary antiviral treatment failure is defined as failure of a drug to reduce HBV DNA levels by ≥1xlog10 IU/ml within 3 months following initiation of therapy, and secondary antiviral treatment failure as a rebound of HBV replication of ≥1xlog10 IU/ml from nadir in patients with an initial antiviral treatment effect (≥1xlog10 IU/ml decrease in serum HBV DNA). Confirmation of antiviral drug failure can be established by sequencing the HBV DNA polymerase and identifying specific genetic markers of antiviral drug resistance. In addition to virological assays, HBV resistance can be assessed from a clinical perspective including increased serum alanine aminotransferase levels and the development of systemic symptoms or signs of liver failure. Potential strategies to prevent the emergence of resistance and how to manage drug-resistant HBV once it emerges are discussed.

show abstract

Section: Table 3 Antiviral Treatment Effect Summarymentioning

confidence: 99%